LYMZUL
Live / Registered — Registered (as of 07 Jan 2025)
What this means for you
Registered since 07 Jan 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 07 Jan 2031: the §8 declaration of use).
Record
- Serial number
- 97877503
- Registration number
- 7637835
- Mark type
- Word mark
- Filed
- 07 Apr 2023
- Published for opposition
- 17 Sept 2024
- Registered
- 07 Jan 2025
- Next maintenance filing
- §8 declaration of use, due by 07 Jan 2031 (grace period to 07 Jul 2031)
- Attorney of record
- Kaitlyn M. Garvin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; chemical preparations for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; injectable pharmaceutical solutions for use as a marker during gastrointestinal endoscopy; injectable pharmaceutical solutions used as a contrast solution for medical imaging procedures; injectable pharmaceutical solutions for medical diagnostic purposes for viewing and marking tissue; injectable pharmaceutical solutions used as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas; injectable pharmaceutical solutions used for polyps or lesions resection medicines for tissue staining; injectable pharmaceutical solutions for use as a marker during visceral surgery; injectable pharmaceutical solutions for the detection of amniotic fluid leaks; injectable pharmaceutical solutions for use as a marker during cystoscopy and ureteral catheterization; injectable pharmaceutical solutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; synthetic peptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics; phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; drug delivery agents in the form of injectable compounds being pharmaceutical solutions in pre-filled vials that facilitate the delivery of pharmaceutical preparations; pre-filled syringes for medical and clinical purposes, sold filled with injectable pharmaceutical solutions for marking tissue by injection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for the antiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation, injection or local application
Owner
- PROVEPHARM LIFE SOLUTIONS, Marseille, FR
- PROVEPHARM LIFE SOLUTIONS, Marseille, FR
- PROVEPHARM LIFE SOLUTIONS, Marseille, FR
Board proceedings on this mark
The owner also pleads this mark in 1 other Board proceeding.
Prosecution history
- 07 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 17 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Sept 2024 — PUBLISHED FOR OPPOSITION
- 28 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Aug 2024 — ASSIGNED TO LIE
- 23 Feb 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 Jan 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 Jan 2024 — NON-FINAL ACTION E-MAILED
- 16 Jan 2024 — NON-FINAL ACTION WRITTEN
- 04 Jan 2024 — ASSIGNED TO EXAMINER
- 02 May 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED